
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5900349/publications.pdf Version: 2024-02-01



Ερις Τλρτομρ

#	Article	IF	CITATIONS
1	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clinical Microbiology and Infection, 2022, 28, 163-177.	6.0	120
2	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	9.4	10
3	STxB as an Antigen Delivery Tool for Mucosal Vaccination. Toxins, 2022, 14, 202.	3.4	10
4	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Cells, 2022, 11, 17.	4.1	7
5	A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project. Nature Medicine, 2022, 28, 882-884.	30.7	7
6	Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2022, 40, 2523-2523.	1.6	2
7	CXCR6 deficiency impairs cancer vaccine efficacy and CD8 ⁺ resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41
8	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Advances, 2021, 5, 1816-1829.	5.2	22
9	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e1337-e1344.	5.8	35
10	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	22.5	80
11	A French cohort for assessing COVID-19 vaccine responses in specific populations. Nature Medicine, 2021, 27, 1319-1321.	30.7	14
12	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, 701273.	4.8	5
13	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. Cancers, 2021, 13, 5562.	3.7	6
14	Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens. Vaccines, 2021, 9, 1412.	4.4	3
15	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer, 2020, 23, 73-81.	5.3	75
16	HPV circulating tumoral DNA quantification by dropletâ€based digital PCR: A promising predictive and prognostic biomarker for HPVâ€associated oropharyngeal cancers. International Journal of Cancer, 2020, 147, 1222-1227.	5.1	65
17	Juvenile-Onset Recurrent Respiratory Papillomatosis Aggressiveness: In Situ Study of the Level of Transcription of HPV E6 and E7. Cancers, 2020, 12, 2836.	3.7	9
18	The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice. Cancer Immunology, Immunotherapy, 2020, 69, 2501-2512.	4.2	5

ERIC TARTOUR

21

#	Article	IF	CITATIONS
19	The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments. Head and Neck Pathology, 2020, 14, 330-340.	2.6	26
20	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	5.1	44
21	PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infectious Diseases, The, 2020, 20, 585-597.	9.1	84
22	Therapeutic cancer vaccine: building the future from lessons of the past. Seminars in Immunopathology, 2019, 41, 69-85.	6.1	56
23	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
24	Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis. Journal of Visualized Experiments, 2019, , .	0.3	4
25	Editorial: Tissue Resident Memory T Cells. Frontiers in Immunology, 2019, 10, 1018.	4.8	22
26	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
27	Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?. Cancers, 2019, 11, 283.	3.7	86
28	Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 871-882.	4.2	29
29	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
30	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 ⁺ Tim-3 ⁺ CD8 ⁺ T Cells. Journal of Visualized Experiments, 2018, , .	0.3	14
31	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
32	Transplantation of Human Embryonic StemÂCell–Derived Cardiovascular Progenitors for SevereÂlschemic LeftÂVentricular Dysfunction. Journal of the American College of Cardiology, 2018, 71, 429-438.	2.8	336
33	New therapeutic targets in the inflammatory microenvironment. ESMO Open, 2018, 3, e000310.	4.5	2
34	Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and) Tj ETQqQ cohort of 348 French squamous cell carcinomas. Human Pathology, 2018, 78, 63-71.) 0 0 rgBT / 2.0	Overlock 10 31
35	High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes. Frontiers in Oncology, 2018, 8, 517.	2.8	19

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering
optimised T-cell responses toward immune-escaped tumours. Nature Communications, 2018, 9, 5097.

#	Article	IF	CITATIONS
37	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer, 2018, 143, 3008-3018.	5.1	16
38	Resident memory T cells, critical components in tumor immunology. , 2018, 6, 87.		193
39	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. Clinical Cancer Research, 2018, 24, 5534-5542.	7.0	15
40	Targeting Resident Memory T Cells for Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1722.	4.8	51
41	HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Modern Pathology, 2018, 31, 1645-1652.	5.5	13
42	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. OncoImmunology, 2017, 6, e1286437.	4.6	28
43	Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nature Communications, 2017, 8, 15221.	12.8	231
44	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large MulticenterÂStudy. Clinical Genitourinary Cancer, 2017, 15, e469-e476.	1.9	11
45	Sunitinib in kidney cancer: 10 years of experience and development. Expert Review of Anticancer Therapy, 2017, 17, 129-142.	2.4	30
46	Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines. Oncolmmunology, 2017, 6, e1358841.	4.6	10
47	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2017, 2, e000213.	4.5	248
48	Immune therapy in colorectal cancer. Colorectal Cancer, 2017, 6, 1-10.	0.8	3
49	In Silico Adjuvant Design and Validation. Methods in Molecular Biology, 2017, 1494, 107-125.	0.9	4
50	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research, 2017, 77, 1075-1082.	0.9	166
51	Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses. PLoS ONE, 2017, 12, e0181403.	2.5	7
52	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines, 2016, 4, 37.	4.4	63
53	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 ⁺ Th1 responses against telomerase in cancer patients. Oncolmmunology, 2016, 5, e1137416.	4.6	21
54	IL-15 <i>Trans</i> -Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists. Journal of Immunology, 2016, 197, 168-178.	0.8	43

#	Article	IF	CITATIONS
55	Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine. Clinical Cancer Research, 2016, 22, 2317-2319.	7.0	3
56	A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice. Clinical Cancer Research, 2016, 22, 4133-4144.	7.0	19
57	Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors. Journal of Controlled Release, 2016, 239, 82-91.	9.9	23
58	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
59	Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. OncoImmunology, 2016, 5, e1164363.	4.6	13
60	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncolmmunology, 2016, 5, e1214790.	4.6	64
61	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.9	42
62	Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncolmmunology, 2016, 5, e1149674.	4.6	46
63	Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines. Clinical Cancer Research, 2016, 22, 530-532.	7.0	27
64	Smoking and the Association Between Depressive Symptoms and Absolute Neutrophil Count in the Investigations Préventives et Cliniques Cohort Study. Psychosomatic Medicine, 2015, 77, 1039-1049.	2.0	12
65	Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	4
66	Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget, 2015, 6, 27832-27846.	1.8	46
67	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. Oncolmmunology, 2015, 4, e998538.	4.6	119
68	Retrograde transport is not required for cytosolic translocation of the B-subunit of Shiga toxin. Journal of Cell Science, 2015, 128, 2373-2387.	2.0	15
69	Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report: Figure 1. European Heart Journal, 2015, 36, 2011-2017.	2.2	383
70	Trial Watch: Peptide-based anticancer vaccines. Oncolmmunology, 2015, 4, e974411.	4.6	97
71	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. Journal of Experimental Medicine, 2015, 212, 139-148.	8.5	836
72	The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. Journal of Immunology, 2015, 195, 1891-1901.	0.8	14

#	Article	IF	CITATIONS
73	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncolmmunology, 2015, 4, e1008814.	4.6	102
74	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	4.6	237
75	Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer. Molecular Cancer Therapeutics, 2015, 14, 1336-1345.	4.1	77
76	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncolmmunology, 2015, 4, e1001236.	4.6	22
77	Trial Watch: Adoptive cell transfer for oncological indications. Oncolmmunology, 2015, 4, e1046673.	4.6	29
78	Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncolmmunology, 2015, 4, e1026531.	4.6	26
79	A meta-analysis of the anterior cingulate contribution to social pain. Social Cognitive and Affective Neuroscience, 2015, 10, 19-27.	3.0	247
80	Control of the Adaptive Immune Response by Tumor Vasculature. Frontiers in Oncology, 2014, 4, 61.	2.8	32
81	Colorectal cancer and immunity: What we know and perspectives. World Journal of Gastroenterology, 2014, 20, 3738.	3.3	105
82	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
83	Consensus guidelines for the detection of immunogenic cell death. Oncolmmunology, 2014, 3, e955691.	4.6	686
84	Trial Watch: Radioimmunotherapy for oncological indications. Oncolmmunology, 2014, 3, e954929.	4.6	40
85	Trial watch: IDO inhibitors in cancer therapy. Oncolmmunology, 2014, 3, e957994.	4.6	223
86	Mucosal vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 2175-2187.	3.3	49
87	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Review of Anticancer Therapy, 2014, 14, 523-542.	2.4	11
88	Control of the Immune Response by Pro-Angiogenic Factors. Frontiers in Oncology, 2014, 4, 70.	2.8	260
89	Trial watch: Dendritic cell-based anticancer therapy. Oncolmmunology, 2014, 3, e963424.	4.6	62
90	Clinical validation of IFNÎ ³ /IL-10 and IFNÎ ³ /IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Human Vaccines and Immunotherapeutics, 2014, 10, 104-113.	3.3	17

#	Article	IF	CITATIONS
91	Immunity and squamous cell carcinoma of the anus: Epidemiological, clinical and therapeutic aspects. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 18-23.	1.5	8
92	Trial Watch. Oncolmmunology, 2014, 3, e28344.	4.6	31
93	Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy, 2014, 16, 427-439.	0.7	27
94	Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends in Pharmacological Sciences, 2014, 35, 163-165.	8.7	36
95	Suppression by Thimerosal of Ex-Vivo CD4+ T Cell Response to Influenza Vaccine and Induction of Apoptosis in Primary Memory T Cells. PLoS ONE, 2014, 9, e92705.	2.5	10
96	A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response. Current Gene Therapy, 2014, 14, 236-246.	2.0	16
97	Arginine administration to critically ill patients with a low nitric oxide fraction in the airways: a pilot study. Intensive Care Medicine, 2013, 39, 1663-1665.	8.2	20
98	Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+T cells. BMC Cancer, 2013, 13, 592.	2.6	16
99	Lung cancer: potential targets for immunotherapy. Lancet Respiratory Medicine,the, 2013, 1, 551-563.	10.7	69
100	PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. Cancer Research, 2013, 73, 128-138.	0.9	554
101	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine, 2013, 5, 172ra20.	12.4	195
102	Le papillomavirus n'attaque pas que les femmes. Revue Francophone Des Laboratoires, 2013, 2013, 50-53.	0.0	0
103	Efficacy of DNA Vaccines Forming E7 Recombinant Retroviral Virus-Like Particles for the Treatment of Human Papillomavirus-Induced Cancers. Human Gene Therapy, 2013, 24, 533-544.	2.7	18
104	An allogeneic NK cell line engineered to express chimeric antigen receptors. OncoImmunology, 2013, 2, e27156.	4.6	4
105	VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. Cancer Research, 2013, 73, 539-549.	0.9	528
106	Trial watch. Oncolmmunology, 2013, 2, e23082.	4.6	130
107	NK cells from pleural effusions are potent antitumor effector cells. European Journal of Immunology, 2013, 43, 331-334.	2.9	14
108	Immunotherapy of HPV-associated head and neck cancer. Oncolmmunology, 2013, 2, e24534.	4.6	12

#	Article	IF	CITATIONS
109	Following up tumor-specific regulatory T cells in cancer patients. Oncolmmunology, 2013, 2, e25444.	4.6	21
110	Trial watch. Oncolmmunology, 2013, 2, e25771.	4.6	150
111	VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncolmmunology, 2013, 2, e25156.	4.6	32
112	Trial Watch. Oncolmmunology, 2013, 2, e26621.	4.6	101
113	Trial Watch. Oncolmmunology, 2013, 2, e24238.	4.6	58
114	Trial Watch. Oncolmmunology, 2013, 2, e25595.	4.6	83
115	Inhibition of the Differentiation of Monocyte-Derived Dendritic Cells by Human Gingival Fibroblasts. PLoS ONE, 2013, 8, e70937.	2.5	19
116	Abstract 3315: Synergistic direct and distant bystander effects contribute to the efficiency of a new suicide gene therapy against cancer , 2013, , .		0
117	Modulation of Immunity by Antiangiogenic Molecules in Cancer. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	94
118	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncolmmunology, 2012, 1, 894-907.	4.6	194
119	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncolmmunology, 2012, 1, 326-333.	4.6	95
120	Trial watch. Oncolmmunology, 2012, 1, 179-188.	4.6	104
121	Trial watch. Oncolmmunology, 2012, 1, 1557-1576.	4.6	110
122	Trial Watch. Oncolmmunology, 2012, 1, 699-739.	4.6	184
123	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research, 2012, 18, 6284-6295.	7.0	54
124	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clinical Cancer Research, 2012, 18, 2943-2953.	7.0	97
125	Trial Watch. Oncolmmunology, 2012, 1, 306-315.	4.6	70
126	Trial Watch. Oncolmmunology, 2012, 1, 493-506.	4.6	86

#	Article	IF	CITATIONS
127	Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 467-473.e2.	0.8	27
128	An unusual human papillomavirus type 82 detection in laryngeal squamous cell carcinoma: Case report and review of literature. Journal of Clinical Virology, 2012, 54, 190-193.	3.1	12
129	Trial watch. Oncolmmunology, 2012, 1, 1111-1134.	4.6	152
130	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	4.6	103
131	Trial watch. Oncolmmunology, 2012, 1, 1323-1343.	4.6	203
132	Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells. Cancer Research, 2012, 72, 2757-2767.	0.9	95
133	Abstract 5388: Local mucosal CD8+T cell response is required to inhibit the growth of orthotopic head and neck and lung cancers. , 2012, , .		0
134	Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors. Blood, 2012, 120, 1446-1446.	1.4	2
135	Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8î±+ dendritic cell subset. Vaccine, 2011, 29, 5892-5903.	3.8	21
136	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. Cancer Research, 2011, 71, 5601-5605.	0.9	341
137	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	4.8	9
138	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 2011, 118, 4853-4862.	1.4	144
139	IL-18 Induces PD-1–Dependent Immunosuppression in Cancer. Cancer Research, 2011, 71, 5393-5399.	0.9	307
140	Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews, 2011, 30, 83-95.	5.9	275
141	A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology, Immunotherapy, 2011, 60, 261-271.	4.2	95
142	Abstract 752: A CCR4 antagonist combined with protein-or DNA-based vaccines efficiently breaks tolerance and elicits CD8+T cells directed against self and viral associated tumor antigens. , 2011, , .		0
143	A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy, 2010, 33, 991-998.	2.4	188
144	Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood, 2010, 115, 3025-3032.	1.4	30

#	Article	IF	CITATIONS
145	Better understanding tumor–host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head and Neck, 2010, 32, 946-958.	2.0	50
146	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. Journal of Immunology, 2010, 185, 418-423.	0.8	30
147	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. Current Topics in Microbiology and Immunology, 2010, 344, 1-24.	1.1	193
148	IMMUNOTHÉRAPIE DES CANCERS. Bulletin De L'Academie Veterinaire De France, 2009, , 363.	0.0	0
149	Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer. Journal of Clinical Oncology, 2009, 27, e5-e6.	1.6	36
150	Characterization of immune functions in TRAF4â€deficient mice. Immunology, 2008, 124, 562-574.	4.4	25
151	Correlation between Shiga toxin Bâ€subunit stability and antigen crosspresentation: A mutational analysis. FEBS Letters, 2008, 582, 185-189.	2.8	3
152	The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer. Cancer Research, 2008, 68, 3907-3914.	0.9	75
153	Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities. Cancer Research, 2008, 68, 3931-3940.	0.9	58
154	A Phase II Study of Tg4010 (Mva-Muc1-II2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 735-744.	1.1	187
155	Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients. Journal of Immunology, 2008, 181, 431-439.	0.8	37
156	Dendritic cell-induced apoptosis of human cytomegalovirus-infected fibroblasts promotes cross-presentation of pp65 to CD8+ T cells. Journal of General Virology, 2008, 89, 78-86.	2.9	20
157	Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures. Journal of Clinical Oncology, 2008, 26, 4410-4417.	1.6	797
158	Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Research, 2008, 18, 104-111.	1.2	27
159	Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients. Journal of Immunotherapy, 2008, 31, 101-112.	2.4	65
160	B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity. Journal of Immunology, 2007, 179, 3371-3379.	0.8	55
161	Correspondence to Creydt VP et al., Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells, Microbes Infect. 8(2) (2006) 410–419. Microbes and Infection, 2006, 8, 2331-2332.	1.9	2
162	The Shiga toxin B-subunit targets antigenin vivo to dendritic cells and elicits anti-tumor immunity. European Journal of Immunology, 2006, 36, 1124-1135.	2.9	80

#	Article	IF	CITATIONS
163	Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers. Clinical Cancer Research, 2006, 12, 465-472.	7.0	517
164	Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses. Clinical Cancer Research, 2006, 12, 3158-3167.	7.0	44
165	Fluorospot Assay: Methodological Analysis. , 2005, 302, 289-296.		8
166	Early Impairment of CD8+T Cells Immune Response Against Epstein–Barr Virus (EBV) Antigens Associated with High Level of Circulating Mononuclear EBV DNA Load in HIV Infection. Journal of Clinical Immunology, 2004, 24, 125-134.	3.8	15
167	Expression and activity of IL-17 in cutaneous T-cell lymphomas(mycosis fungoides and sezary) Tj ETQq1 1 0.7843	14 rgBT /	Overlock 10
168	Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Human Immunology, 2004, 65, 1307-1318.	2.4	23
169	A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. Journal of Immunological Methods, 2003, 283, 91-98.	1.4	98
170	Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. Journal of Gene Medicine, 2003, 5, 690-699.	2.8	164
171	The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. International Immunology, 2003, 15, 1161-1171.	4.0	59
172	Interleukin-17 inhibits tumor cell growth by means of a T-cell–dependent mechanism. Blood, 2002, 99, 2114-2121.	1.4	309
173	1st Class Ticket to Class I: Protein Toxins as Pathfinders for Antigen Presentation. Traffic, 2002, 3, 697-704.	2.7	49
174	Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer. Journal of Immunotherapy, 2000, 23, 570-580.	2.4	123
175	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. Immunology Letters, 2000, 75, 1-8.	2.5	10
176	The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens. Journal of Immunology, 2000, 165, 3301-3308.	0.8	132
177	Control of tumor development by intratumoral cytokines. Immunology Letters, 1999, 68, 135-139.	2.5	27
178	Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Therapy, 1999, 6, 271-281.	4.6	28
179	Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells. Journal of Immunological Methods, 1999, 227, 149-160.	1.4	6
180	Defective IL2 Gene Expression in Newborn is Accompanied with Impaired Tyrosine-Phosphorylation in T Cells. Pediatric Research, 1999, 45, 409-413.	2.3	13

#	Article	IF	CITATIONS
181	Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. European Journal of Immunology, 1998, 28, 2726-2737.	2.9	86
182	In vivo induction of functional Fcl̂ ³ RI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). British Journal of Haematology, 1998, 100, 550-556.	2.5	27
183	Prognostic Value of Intratumoral Interferon Gamma Messenger RNA Expression in Invasive Cervical Carcinomas. Journal of the National Cancer Institute, 1998, 90, 287-294.	6.3	80
184	Cytokines and cell regulation. Molecular Aspects of Medicine, 1997, 18, 1-90.	6.4	14
185	IL-6 is a survival prognostic factor in renal cell carcinoma. Immunology Letters, 1997, 58, 121-124.	2.5	43
186	Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma. , 1997, 79, 1401-1408.		25
187	Regulation of CD44 Isoform Expression and CD44-Mediated Signaling in Human Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 83-90.	1.6	8
188	Decreased frequency of HLA-DRB 1*13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. , 1996, 69, 159-164.		74
189	Variable expression of CD3-ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with til phenotype and function. International Journal of Cancer, 1995, 63, 205-212.	5.1	101
190	Phenotypic and Functional Analysis of Tumour-Infiltrating Lymphocytes from Patients with Renal Cell Carcinoma. European Urology, 1994, 25, 151-157.	1.9	2
191	Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. Cancer, 1993, 72, 3296-3303.	4.1	43
192	Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (FcγR) encoded by an alternatively spliced transcript of the FcγRII gene. International Immunology, 1993, 5, 859-868.	4.0	25
193	Soluble FcγR (sFcγR): Detection in Biological Fluids and Production of a Murine Recombinant sFcγR Biologically Active in vitro and in vivo. Immunobiology, 1992, 185, 207-221.	1.9	23
194	Murine soluble Fcl ³ receptors/IgG-binding factors (IgG-BF): Analysis of the relation to Fcl ³ RII and production of milligram quantities of biologically active recombinant IgG-BF. Immunologic Research, 1992, 11, 181-190.	2.9	7